Risk of major adverse cardiovascular events within a 1-year follow-up period in the model 1 matched population
| HZ vaccine | No HZ vaccine | ||||
| n | No. of event | n | No. of event | HR (95% CI) | |
| Follow-up period (month) | |||||
| 1 | 45 958 | 69 | 45 958 | 314 | 0.21 (0.16 to 0.27) |
| 3 | 45 958 | 218 | 45 958 | 575 | 0.35 (0.30 to 0.41) |
| 6 | 45 958 | 404 | 45 958 | 813 | 0.45 (0.40 to 0.50) |
| 9 | 45 958 | 612 | 45 958 | 1014 | 0.54 (0.48 to 0.59) |
| 12 | 45 958 | 790 | 45 958 | 1228 | 0.57 (0.52 to 0.62) |
Model 1 indicates any HZ vaccination versus non-HZ vaccination population.
HZ, herpes zoster.